CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung...
Phase 1, Phase 2
Westwood, Kansas, United States and 9 other locations
in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who ha...
Phase 2
Kansas City, Missouri, United States and 157 other locations
as a single agent and in combination with pembrolizumab in subjects with locally advanced and unresectable or metastatic non-small cell lung ...
Phase 1
Kansas City, Kansas, United States and 18 other locations
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the ...
Phase 3
Kansas City, Missouri, United States and 290 other locations
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival ...
Phase 2, Phase 3
Westwood, Kansas, United States and 60 other locations
of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung...
Phase 3
Fairway, Kansas, United States and 128 other locations
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer...
Phase 3
Kansas City, Missouri, United States and 334 other locations
and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung...
Phase 1, Phase 2
Fairway, Kansas, United States and 43 other locations
for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due to muta...
Phase 3
Kansas City, Kansas, United States and 152 other locations
advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR m...
Phase 2
Kansas City, Missouri, United States and 36 other locations
Clinical trials
Research sites
Resources
Legal